AZD8330 First Time in Man in Patients With Advanced Malignancies

• Status: Completed
• Trial end date: 2011-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary purpose of this protocol is to investigate the safety and tolerability of AZD8330 (ARRY-424704) in patients with Advanced Malignancies

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca

Criteria

Inclusion Criteria:

• Cancer which is refractory to standard therapies, or no therapies exist;

Exclusion Criteria:

• Participated in radiotherapy, biological or chemotherapy within 21 days prior to study start;

• Hasn't participated in investigation drug study within 30 days;

• Brain metastases/spinal cord compression unless treated and stable,

• Off steroids/anticonvulsants.